Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.

ABSTRACT:

Background

Treatment-related skin reactions (TRSRs) induced by enfortumab vedotin (EV) targeting nectin-4 are among the most common adverse events. However, their association with survival and treatment response is poorly understood.

Methods

We retrospectively identified patients who received EV from December 2021 to April 2023 at Nagoya University Hospital and its affiliated facilities and extracted clinical data from their medical records. We evaluated cancer-specific survival (CSS) and progression-free survival (PFS) as survival outcomes and overall response rate (ORR) and disease control rate (DCR) as treatment responses between patients with and without TRSRs.

Results

In total, 67 eligible patients were identified. Thirty-four patients experienced TRSRs, and the

SUBMITTER: Nagayama J 

PROVIDER: S-EPMC11785594 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature